-The Hindu Gross domestic expenditure on research has stayed at 0.7% of the GDP for years While India has made ‘solid progress’ towards the Sustainable Development Goal (SDG) targets concerning industry, infrastructure and innovation, the country’s investment in research remains unsatisfactory, the UNESCO Science Report has observed. The gross domestic expenditure on research (GERD) has been stagnant at 0.7% of the GDP for years, although, in absolute terms, research expenditure has increased, the...

A recent report by the International Food Policy Research Institute (IFPRI) states that the countrywide lockdown imposed on 25th March, 2020, which was extended for nearly two months in phases, affected the food and nutritional status of vulnerable sections of the Indian population. It says that a programme like the Mid-Day Meal Scheme covers four-fifth of primary-school-aged children in the country that helps in improving not only nutrition but also...

-Hindustan Times The second wave will deepen inequality. Expand support to states, universalise PDS, and ramp up MGNREGS now Abandoned by the State that insisted on locking down, refusing to recognise the damage done to their livelihoods, India’s workers asserted their rights and made themselves heard by walking home in March 2020. The long march home was emblematic of the suffering and hardship unleashed by the first wave. A year later, it is...

-The Indian Express A waiver on IP protections would mean pharmaceutical firms and vaccine makers across the world can learn how to make these vaccines without fear of lawsuits from companies that originally developed them. In a move that could potentially help increase production of Covid-19 vaccines around the world, the United States on Wednesday announced its support for waiving intellectual property (IP) protections for these vaccines. Subsequently, the European Union (EU) agreed...

-The Hindu Business Line It’s only an open-ended deal with co-developer Bharat Biotech, says top source The Indian Council of Medical Research (ICMR) is willing to share the know-how to produce the indigenously-developed Covid-19 vaccine, Covaxin, with any company as the contract with co-developer Bharat Biotech is not close-ended. Currently, Bharat Biotech has the sole licence to manufacture Covaxin, which it developed in collaboration with scientists from ICMR’s Pune-based National Institute of Virology...